Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




BioMérieux Acquires Oncology and Theranostics Company

By LabMedica International staff writers
Posted on 06 Oct 2008
BioMérieux, (Marcy l'Etoile, France) acquired full ownership of the privately held AviaraDx, Inc., (San Diego, CA, USA), a molecular in vitro diagnostics company, for US$60 million. More...
The acquisition will help bioMérieux gain validated cancer biomarkers as well as capabilities in gene expression profiling in tissues for applications in oncology. AviaraDx's diagnostic tests are used in the molecular classification of cancers and assist oncologists in making critical therapeutic decisions.

AviaraDx will remain as an independent legal entity called bioTheranostics, Inc. Richard Ding, bioMérieux's corporate vice president of business development and theranostics, has been named CEO of bioTheranostics. He will also continue to serve as a member of the bioMérieux management committee and to lead bioMérieux's business development and theranostics activities.

AviaraDx has built a molecular research and development lab and small sales and marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments- (CLIA)-certified service lab. It has two innovative products on the market: Aviara CancerType ID, which provides improved cancer classification, especially for patients diagnosed with metastatic cancer where the origin is uncertain or unknown; IndexSM, which offers a combined assessment of two Aviara markers (H/I and MGI) for risk prognosis and treatment response prediction for chemo- and hormonal therapy. H/I markers provide assessment of endocrine resistance (ER) and risk of recurrence in certain breast cancers and MGI gives an assessment of the chemosensitivity, tumor grade, and prediction in ER and other breast cancers.

The acquisition of AviaraDX puts bioMérieux in a position to offer a wide range of high-value tools for cancer management, which help oncologists make relevant clinical decisions in their daily practice: the widely installed Vidas immunoassay platform and molecular diagnostics with the NucliSens range together with AviaraDx technologies.

"The acquisition of AviaraDx is a major milestone in bioMérieux's long-term growth strategy. Their molecular technology in tumor tissue and broad clinical capabilities will help us achieve Dr. Christophe Mérieux's vision of providing patients with personalized, predictive medicine,” stated Stéphane Bancel, CEO of bioMérieux. "We are also very excited to welcome the talented AviaraDx team to bioMérieux,” he added.

Related Links:
bioMérieux
AviaraDx


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.